Bond Benjamin W, Duric Bea, Spinazzola Edoardo, Trotta Giulia, Chesney Edward, Li Zhikun, Quattrone Diego, Tripoli Giada, Gayer-Anderson Charlotte, Rodriguez Victoria, Ferraro Laura, La Cascia Caterina, Tarricone Ilaria, Szöke Andrei, Arango Celso, Bobes Julio, Bernardo Miquel, Del-Ben Cristina Marta, Menezes Paulo Rossi, Selten Jean-Paul, Rutten Bart P F, de Haan Lieuwe, Stilo Simona, Schürhoff Franck, Pignon Baptiste, Freeman Tom P, Vassos Evangelos, Murray Robin M, Austin-Zimmerman Isabelle, Di Forti Marta
Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
South London and Maudsley NHS Mental Health Foundation Trust, London, UK.
Can J Psychiatry. 2025 Mar;70(3):182-193. doi: 10.1177/07067437241290187. Epub 2025 Jan 15.
To establish whether the risk of psychotic disorders in cannabis users changes with time following cannabis cessation using data from the European Network of National Networks studying Gene-Environment Interactions in Schizophrenia (EU-GEI) case-control study.
The EU-GEI case-control study collected data from first episode psychosis patients and population controls across sites in Europe and Brazil between May 2010 and April 2015. Adjusted logistic regressions were applied to examine whether the odd of psychosis case status changed: (1) with time following cannabis cessation and (2) across different cannabis use groups.
Psychosis risk declined following cessation of cannabis use (β = -0.002; 95% CI -0.004 to 0.000; = 0.067). When accounting for duration of use, this effect remained (β = -0.003; 95% CI -0.005 to -0.001; = 0.013). However, in models adjusting for frequency and potency of use the result was not significant. Analysis of different cannabis use groups indicated that ex-users who stopped 1 to 4 weeks previously had the highest risk for psychotic disorder compared to never users (OR = 6.89; 95% CI 3.91-12.14; < 0.001); risk declined for those who stopped 5 to 12 weeks previously (OR = 2.70; 95% CI 1.73-4.21; < 0.001) and 13 to 36 weeks previously (OR = 1.53; 95% CI 1.00-2.33; = 0.050). Ex-users who stopped 37 to 96 weeks (OR = 1.01; 95% CI 0.66-1.57; = 0.949), 97 to 180 weeks (OR = 0.73; 95% CI 0.45-1.19; = 0.204), and 181 weeks previously or more (OR = 1.18; 95% CI 0.76-1.83; = 0.456) had similar psychosis risk to those who had never-used cannabis.
Risk of psychotic disorder appears to decline with time following cannabis cessation, receding to that of those who have never used cannabis after 37 weeks or more of abstinence. Although, preliminary results suggest that frequent users of high potency types of cannabis might maintain an elevated risk compared to never users even when abstaining for longer than 181 weeks.
利用欧洲精神分裂症基因-环境相互作用研究国家网络联盟(EU-GEI)病例对照研究的数据,确定大麻使用者患精神障碍的风险在停止使用大麻后是否随时间变化。
EU-GEI病例对照研究于2010年5月至2015年4月期间收集了欧洲和巴西各研究点的首发精神病患者及人群对照的数据。应用校正逻辑回归分析来检验精神病病例状态的比值是否发生变化:(1)随停止使用大麻后的时间变化;(2)在不同大麻使用组之间。
停止使用大麻后患精神病的风险下降(β=-0.002;95%置信区间为-0.004至0.000;P=0.067)。在考虑使用时长后,该效应仍然存在(β=-0.003;95%置信区间为-0.005至-0.001;P=0.013)。然而,在调整使用频率和效力的模型中,结果并不显著。对不同大麻使用组的分析表明,与从未使用者相比,在1至4周前停止使用大麻的既往使用者患精神障碍的风险最高(比值比[OR]=6.89;95%置信区间为3.91至12.14;P<0.001);在5至12周前停止使用大麻的使用者风险下降(OR=2.70;95%置信区间为1.73至4.21;P<0.001),在13至36周前停止使用大麻的使用者风险也下降(OR=1.53;95%置信区间为1.00至2.33;P=0.050)。在37至96周前(OR=1.01;95%置信区间为0.66至1.57;P=0.949)、97至180周前(OR=0.73;95%置信区间为0.45至1.19;P=0.204)以及181周前或更早之前停止使用大麻的既往使用者,其患精神病的风险与从未使用过大麻的人相似。
停止使用大麻后患精神障碍的风险似乎随时间下降,在戒断37周或更长时间后降至从未使用过大麻者的水平。不过,初步结果表明,即使戒断超过181周,与从未使用者相比,频繁使用高效力类型大麻的人可能仍维持较高风险。